Efficacy of whole-brain radiotherapy with or without simultaneous integrated boost in non-small cell lung cancer with brain metastases: a retrospective analysis.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
119 patients with NSCLC-BM treated between 2019 and 2025 were retrospectively analyzed.
I · Intervention 중재 / 시술
WBRT-SIB achieved significantly longer local PFS compared with those treated with WBRT ( = 0
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] WBRT-SIB provided comparable overall intracranial control to conventional WBRT but achieved superior local tumor control in patients with limited brain metastases (< 8 lesions). These findings support WBRT-SIB as a promising option for selected NSCLC-BM patients, warranting validation in prospective studies.
[BACKGROUND] Whole-brain radiotherapy (WBRT) remains a cornerstone in the management of brain metastases (BMs) from non-small cell lung cancer (NSCLC), and WBRT with simultaneous integrated boost (WBR
APA
Zhao B, Zhang M, et al. (2025). Efficacy of whole-brain radiotherapy with or without simultaneous integrated boost in non-small cell lung cancer with brain metastases: a retrospective analysis.. Frontiers in medicine, 12, 1733289. https://doi.org/10.3389/fmed.2025.1733289
MLA
Zhao B, et al.. "Efficacy of whole-brain radiotherapy with or without simultaneous integrated boost in non-small cell lung cancer with brain metastases: a retrospective analysis.." Frontiers in medicine, vol. 12, 2025, pp. 1733289.
PMID
41601802 ↗
Abstract 한글 요약
[BACKGROUND] Whole-brain radiotherapy (WBRT) remains a cornerstone in the management of brain metastases (BMs) from non-small cell lung cancer (NSCLC), and WBRT with simultaneous integrated boost (WBRT-SIB) emerges as a promising strategy that aims to improve local tumor control through dose escalation while maintaining the coverage of subclinical disease offered by WBRT in theory. However, current evidence regarding the efficacy of WBRT-SIB remains inconclusive. This study aimed to compare the intracranial efficacy of WBRT and WBRT-SIB in NSCLC patients with BMs.
[METHODS] Clinical data from 119 patients with NSCLC-BM treated between 2019 and 2025 were retrospectively analyzed. Local progression-free survival (local PFS) was the primary endpoint, while distant PFS and intracranial PFS (iPFS) were secondary endpoints. Propensity score matching (PSM) was performed to balance baseline characteristics. Kaplan-Meier and Cox regression analyses were applied to identify prognostic factors.
[RESULTS] No significant differences were observed in local PFS, distant PFS, or iPFS between the WBRT and WBRT-SIB groups, both before and after PSM (all > 0.05). Subgroup analysis revealed that patients with fewer than eight BMs who received WBRT-SIB achieved significantly longer local PFS compared with those treated with WBRT ( = 0.043), along with a trend toward improved iPFS that did not reach statistical significance ( = 0.066). Furthermore, anti-angiogenic therapy showed a trend as a protective factor for local PFS without reaching statistical significance ( = 0.086).
[CONCLUSION] WBRT-SIB provided comparable overall intracranial control to conventional WBRT but achieved superior local tumor control in patients with limited brain metastases (< 8 lesions). These findings support WBRT-SIB as a promising option for selected NSCLC-BM patients, warranting validation in prospective studies.
[METHODS] Clinical data from 119 patients with NSCLC-BM treated between 2019 and 2025 were retrospectively analyzed. Local progression-free survival (local PFS) was the primary endpoint, while distant PFS and intracranial PFS (iPFS) were secondary endpoints. Propensity score matching (PSM) was performed to balance baseline characteristics. Kaplan-Meier and Cox regression analyses were applied to identify prognostic factors.
[RESULTS] No significant differences were observed in local PFS, distant PFS, or iPFS between the WBRT and WBRT-SIB groups, both before and after PSM (all > 0.05). Subgroup analysis revealed that patients with fewer than eight BMs who received WBRT-SIB achieved significantly longer local PFS compared with those treated with WBRT ( = 0.043), along with a trend toward improved iPFS that did not reach statistical significance ( = 0.066). Furthermore, anti-angiogenic therapy showed a trend as a protective factor for local PFS without reaching statistical significance ( = 0.086).
[CONCLUSION] WBRT-SIB provided comparable overall intracranial control to conventional WBRT but achieved superior local tumor control in patients with limited brain metastases (< 8 lesions). These findings support WBRT-SIB as a promising option for selected NSCLC-BM patients, warranting validation in prospective studies.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- PTCMIL: multiple instance learning via prompt token clustering for whole slide image analysis.
- Retraction Note: circGIGYF1 inhibits stemness and metastasis in colorectal cancer by promoting WWP2-HOXD13 interaction to regulate β-catenin signalling.
- NIR-II AIEgens for Phototheranostics: Design, Applications and Perspectives.
- Prognostic implications of dominant lesion misidentification in multiple primary lung cancer.
- HBV Precore G1896A Mutation Promotes Malignancy of Hepatocellular Carcinoma by Activating Endoplasmic Reticulum Stress to Enhance Aerobic Glycolysis.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Association of immune-related adverse events with survival in patients receiving immune checkpoint inhibitor plus chemotherapy for lung cancer.
- Unraveling the Enigma of Melanoma Brain Metastasis: New Molecular Insights and Therapeutic Directions.
- DIP-like Adenocarcinoma Presenting as a Part-Solid Nodule: A Case Report.
- NRF2 pathway activation predicts poor prognosis in lung cancer: a cautionary note on antioxidant interventions.
- Dynamic fluorine-18 fluorodeoxyglucose PET for evaluating different-sized metastatic lymph nodes in patients with non-small cell lung cancers.
- Impact of race/ethnicity and the presence of immune-related adverse events on outcomes for non-small cell lung cancer patients treated with immune checkpoint inhibitors.